• 1
    Penn I. Cancers in renal transplant recipients. Adv Ren Replace Ther 2000; 7: 147156.
  • 2
    Penn I. Occurrence of cancers in immunosuppressed organ transplant recipients. Clin Transpl 1998; 12: 147158.
  • 3
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905913.
  • 4
    Opelz G, Dohler B. Lymphomas after solid organ transplantation: A collaborative transplant study report. Am J Transplant 2004; 4: 222230.
  • 5
    Caillard S, Pencreach S, Braun L et al. Simultaneous development of lymphoma in recipients of renal transplants from a single donor: Donor origin confirmed by human leukocytes antigen staining and microsatellite analysis. Transplantation 2005; 79: 7984.
  • 6
    Dotti G, Fiocchi R, Motta T et al. Lymphomas occurring late after solid-organ transplantation: Influence of treatment on the clinical outcome. Transplantation 2002; 74: 10951102.
  • 7
    Ho M, Miller G, Atchison RW et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: The role of primary infection. J Infect Dis 1985; 152: 876886.
  • 8
    Bustami RT, Ojo AO, Wolfe RA et al. Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant 2004; 4: 8793.
  • 9
    Cherikh WS, Kauffman HM, McBride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 12891293.
  • 10
    Buda A, Caforio A, Calabrese F et al. Lymphoproliferative disorders in heart transplant recipients: Role of hepatitis C virus (HCV) and Epstein-Barr virus (EBV) infection. Transpl Int 2000; 13 (Suppl 1): S402S405.
  • 11
    Duvoux C, Pageaux GP, Vanlemmens C et al. Risk factors for lymphoproliferative disorders after liver transplantation in adults: An analysis of 480 patients. Transplantation 2002; 74: 11031109.
  • 12
    Manez R, Breinig MC, Linden P et al. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: The role of cytomegalovirus disease. J Infect Dis 1997; 176: 14621467.
  • 13
    Knowles DM. Immunodeficiency-associated lymphoproliferative disorders. Mod Pathol 1999; 12: 200217.
  • 14
    Caillard S, Dharnidharka V, Agodoa L, Bohen E, Abbott K. Post-transplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 2005; 80: 12331243.
  • 15
    Bakker NA, Van Imhoff GW, Verschuuren EA et al. Early onset post-transplant lymphoproliferative disease is associated with allograft localization. Clin Transplant 2005; 19: 327334.
  • 16
    Trofe J, Buell JF, Beebe TM et al. Analysis of factors that influence survival in post-transplant lymphoproliferative disorder in renal transplant recipients: The Israel Penn Transplant Tumor Registry experience. Am J Transplant 2005; 5: 775780.
  • 17
    Ghobrial I, Habermann T, Ristow K et al. Prognostic factors in patients with post-transplant lymphoproliferative disorders (PTLD) in the rituximab era. Leuk Lymphoma 2005; 46: 191196.
  • 18
    Leblond V, Davi F, Charlotte F et al. Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: A distinct entity? J Clin Oncol 1998; 16: 20522059.
  • 19
    Dotti G, Fiocchi R, Motta T et al. Epstein-Barr virus-negative lymphoproliferate disorders in long-term survivors after heart, kidney, and liver transplant. Transplantation 2000; 69: 827833.